Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

stopping the Dominio effect — A labeling update approved just before patent expiry may have caused Lyrica generics to be cleared later than expected in the US . • Source: Shutterstock

An well-timed labeling update by Lyrica sponsor Pfizer Inc. appears to have allowed the company to squeeze a few more days of monopoly conditions out of the product in the US before generic competition arrived.

Patent protection on Lyrica (pregabalin) was set to expire 30 June and nine generic companies were ready with competitors. But US Food and Drug Administration approval appears to have been...

Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

More from Generics

More from Biosimilars & Generics